Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

986 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trial of Solanezumab in Preclinical Alzheimer's Disease.
Sperling RA, Donohue MC, Raman R, Rafii MS, Johnson K, Masters CL, van Dyck CH, Iwatsubo T, Marshall GA, Yaari R, Mancini M, Holdridge KC, Case M, Sims JR, Aisen PS; A4 Study Team. Sperling RA, et al. Among authors: masters cl. N Engl J Med. 2023 Sep 21;389(12):1096-1107. doi: 10.1056/NEJMoa2305032. Epub 2023 Jul 17. N Engl J Med. 2023. PMID: 37458272 Free PMC article. Clinical Trial.
Blood-based protein biomarkers for diagnosis of Alzheimer disease.
Doecke JD, Laws SM, Faux NG, Wilson W, Burnham SC, Lam CP, Mondal A, Bedo J, Bush AI, Brown B, De Ruyck K, Ellis KA, Fowler C, Gupta VB, Head R, Macaulay SL, Pertile K, Rowe CC, Rembach A, Rodrigues M, Rumble R, Szoeke C, Taddei K, Taddei T, Trounson B, Ames D, Masters CL, Martins RN; Alzheimer's Disease Neuroimaging Initiative; Australian Imaging Biomarker and Lifestyle Research Group. Doecke JD, et al. Among authors: masters cl. Arch Neurol. 2012 Oct;69(10):1318-25. doi: 10.1001/archneurol.2012.1282. Arch Neurol. 2012. PMID: 22801742 Free PMC article.
The amyloid-β pathway in Alzheimer's disease: a plain language summary.
Hampel H, Hu Y, Hardy J, Blennow K, Chen C, Perry G, Kim SH, Villemagne VL, Aisen P, Vendruscolo M, Iwatsubo T, Masters CL, Cho M, Lannfelt L, Cummings JL, Vergallo A. Hampel H, et al. Among authors: masters cl. Neurodegener Dis Manag. 2023 Jun;13(3):141-149. doi: 10.2217/nmt-2022-0037. Epub 2023 Mar 30. Neurodegener Dis Manag. 2023. PMID: 36994753 Free PMC article. Review.
Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease.
Chen CD, McCullough A, Gordon B, Joseph-Mathurin N, Flores S, McKay NS, Hobbs DA, Hornbeck R, Fagan AM, Cruchaga C, Goate AM, Perrin RJ, Wang G, Li Y, Shi X, Xiong C, Pontecorvo MJ, Klein G, Su Y, Klunk WE, Jack C, Koeppe R, Snider BJ, Berman SB, Roberson ED, Brosch J, Surti G, Jiménez-Velázquez IZ, Galasko D, Honig LS, Brooks WS, Clarnette R, Wallon D, Dubois B, Pariente J, Pasquier F, Sanchez-Valle R, Shcherbinin S, Higgins I, Tunali I, Masters CL, van Dyck CH, Masellis M, Hsiung R, Gauthier S, Salloway S, Clifford DB, Mills S, Supnet-Bell C, McDade E, Bateman RJ, Benzinger TLS; DIAN-TU Study Team. Chen CD, et al. Among authors: masters cl. Eur J Nucl Med Mol Imaging. 2023 Jul;50(9):2669-2682. doi: 10.1007/s00259-023-06209-0. Epub 2023 Apr 5. Eur J Nucl Med Mol Imaging. 2023. PMID: 37017737 Free PMC article. Clinical Trial.
Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force.
Angioni D, Hansson O, Bateman RJ, Rabe C, Toloue M, Braunstein JB, Agus S, Sims JR, Bittner T, Carrillo MC, Fillit H, Masters CL, Salloway S, Aisen P, Weiner M, Vellas B, Gauthier S. Angioni D, et al. Among authors: masters cl. J Prev Alzheimers Dis. 2023;10(3):418-425. doi: 10.14283/jpad.2023.68. J Prev Alzheimers Dis. 2023. PMID: 37357282
Accuracy of TrUE-Net in comparison to established white matter hyperintensity segmentation methods: An independent validation study.
Strain JF, Rahmani M, Dierker D, Owen C, Jafri H, Vlassenko AG, Womack K, Fripp J, Tosun D, Benzinger TLS, Weiner M, Masters C, Lee JM, Morris JC, Goyal MS; ADOPIC and ADNI Investigators. Strain JF, et al. Neuroimage. 2024 Jan;285:120494. doi: 10.1016/j.neuroimage.2023.120494. Epub 2023 Dec 10. Neuroimage. 2024. PMID: 38086495 Free article.
Identifying individuals with non-Alzheimer's disease co-pathologies: A precision medicine approach to clinical trials in sporadic Alzheimer's disease.
Tosun D, Yardibi O, Benzinger TLS, Kukull WA, Masters CL, Perrin RJ, Weiner MW, Simen A, Schwarz AJ; Alzheimer's Disease Neuroimaging Initiative. Tosun D, et al. Among authors: masters cl. Alzheimers Dement. 2024 Jan;20(1):421-436. doi: 10.1002/alz.13447. Epub 2023 Sep 4. Alzheimers Dement. 2024. PMID: 37667412 Free PMC article.
Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ-PET, neurodegeneration, and cognition.
Chatterjee P, Vermunt L, Gordon BA, Pedrini S, Boonkamp L, Armstrong NJ, Xiong C, Singh AK, Li Y, Sohrabi HR, Taddei K, Molloy M, Benzinger TLS, Morris JC, Karch C, Berman S, Chhatwal J, Cruchaga C, Graff-Radford NR, Day GS, Farlow M, Fox N, Goate A, Hassenstab J, Lee JH, Levin J, McDade E, Mori H, Perrin R, Sanchez-Valle R, Schofield PR, Levey A, Jucker M, Masters CL, Fagan AM, Bateman RJ, Martins RN, Teunissen C; Dominantly Inherited Alzheimer Network. Chatterjee P, et al. Among authors: masters cl. Alzheimers Dement. 2023 Jul;19(7):2790-2804. doi: 10.1002/alz.12879. Epub 2022 Dec 28. Alzheimers Dement. 2023. PMID: 36576155
Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
Chatterjee P, Pedrini S, Doecke JD, Thota R, Villemagne VL, Doré V, Singh AK, Wang P, Rainey-Smith S, Fowler C, Taddei K, Sohrabi HR, Molloy MP, Ames D, Maruff P, Rowe CC, Masters CL, Martins RN; AIBL Research Group. Chatterjee P, et al. Among authors: masters cl. Alzheimers Dement. 2023 Apr;19(4):1117-1134. doi: 10.1002/alz.12724. Epub 2022 Jul 21. Alzheimers Dement. 2023. PMID: 36574591
986 results